In a nationally representative NHANES sample, inflammatory back pain (IBP) was not associated with HLA-B27 positivity or elevated CRP, regardless of IBP criteria used (e.g., Berlin 8a: OR 0.88, p=0.876). IBP alone may be insufficient for identifying axSpA-related immunogenetic or https://t.co/82NjVU171z

What can we learn from longitudinal peripheral blood multi-omic profiling in at-risk individuals? 50 RA converters vs. non converters from StopRA study Decision tree showing highest risk for conversion to clinical RA in Individuals w/ -CCP3 ≥108 units -T peripheral helpers https://t.co/jw53EB6tI6

#0774 Multi-omic profiling of anti-CCP3+ “at-risk” individuals reveals Tph & cytotoxic CD8+ expansions, altered gene/chromatin profiles and predictive model (AUC 0.77) for RA conversion PTPN22 locus accessibility & Tph ≥ 2.45% identify highest risk. @RheumNow #ACR25 https://t.co/JDSMkdmoGv

A new marker for stratification of ILD in dermatomyositis: Anti MDA5 antibodies! Japanese study MDA5 (201-300) positivity associated w/ Lower 6-month progression-free survival (43% vs. 74%) Lower 5-year survival rates (34% vs. 66%) Validation in other populations awaited https://t.co/IBiYyATer4

Dr. Werth on the #SLE guidelines on tx of cutaneous LE: 🔅All patients should be on hydroxychloroquine unless with CI. ☝️Important! For SLE pts presenting with new-onset rashes, review/ask about medications; consider drug-induced SCLE. #ACR25 @RheumNow https://t.co/ok5jAi7uO0

Getting down with Jack at the @RheumNow #ACR25 stand - come and say hello! (and Ask Cush Anything - scan the QR code, and maybe end up on the podcast!) https://t.co/0u0boHIIR3

#ACR25 In a rush and wondering which abstract to look out for pertaining to new update on Biologics in #SLE #lupus? Please find my article on conference preview @RheumNow https://t.co/usIXPsj5bm https://t.co/4wmWvDyv83

Come to our first #HealthLiteracy poster of #ACR25! #0190 Cluster analysis >900 people with IA Lowest health literacy cluster assoc w: 4× ⬆️anxiety/depression 2× ⬆️disease activity, vs highest HL Higher HL assoc w older age & ⬆️comorbidities but fewer mental health Sx @RheumNow https://t.co/iIRXaOl4qZ

#0773 Anti-MDA5 epitope mapping identifies key regions (aa 201-300, 601-700) linked to treatment resistance & poor prognosis in DM-ILD and even IIPs. Epitope-specific antibodies could refine risk stratification & guide therapy in ILD beyond autoimmune disease. @RheumNow #ACR25 https://t.co/moRffVGZPn

#ACR25 Abstr#0772. Should we be worried of #SLE patients with low uPCR 0.25-0.49? Kidney biopsy in N=28 + poor prognostic (Non-White, active serology or active sediment) - 71% had LN (No class IV or Mixed) - 46% actionable LN Cost-effectiveness data needed. #ACRBest @RheumNow https://t.co/Bt3fuA3aJh